Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.44 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.44 |
| ▸ | CCR3 | P51677 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | GCK | P35557 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20971863 | 0.90 | MEN1 (0.48) | KMT2AMEN1SMN1; SMN2PIK3CGCCR3 | |
| SCHEMBL20996927 | 0.89 | GPR6 (0.46) | KMT2AMEN1SMN1; SMN2PIK3CGCCR3 | |
| SCHEMBL20997053 | 0.87 | MAPT (0.43) | CCR3TP53EPHX2 | |
| SCHEMBL20996297 | 0.84 | MEN1 (0.62) | KMT2AMEN1SMN1; SMN2CCR3 | |
| SCHEMBL20971839 | 0.81 | MEN1 (0.44) | KMT2AMEN1SMN1; SMN2CCR3 | |
| SCHEMBL20997054 | 0.80 | THRB (0.48) | TP53NPC1GSK3B | |
| SCHEMBL3587135 | 0.79 | PIK3CG (0.52) | KMT2AMEN1SMN1; SMN2PIK3CGRYR2 | |
| SCHEMBL20971793 | 0.79 | FAAH (0.44) | CCR3GSK3B | |
| SCHEMBL20971797 | 0.79 | OPRM1 (0.44) | NPC1 | |
| SCHEMBL20996950 | 0.79 | EPHX2 (0.50) | KMT2AMEN1CCR3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190142810-A1 | MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF PROLIFERATION DISORDERS | BASILEA PHARM INT AG (CH) | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190142810-A1 | MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF PROLIFERATION DISORDERS | NDUFAB1, FH, MT-ND1 | KMT2A 2480/4885MEN1 1271/4885SMN1; SMN2 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.